TheraVet Signs an International Distribution Agreement for BIOCERA-VET® Covering 24 Countries
21 February 2023 - 05:30PM
Business Wire
- Agreement signed with Vetpharma, a highly qualified team
with a robust distribution network in support of
commercialization
- BIOCERA-VET® now available in all continents
- New high potential territories: Scandinavian countries,
Brazil, South Africa, Australia and Japan
Regulatory News:
TheraVet (ISIN: BE0974387194 – ticker: ALVET) (Paris:ALVET)
(Brussels:ALVET), a pioneering company in the management of
osteoarticular diseases in pets, announces today the signing of
an exclusive distribution agreement with Vetpharma, a leading
company in the marketing of veterinary products. This agreement
represents a significant step forward for the distribution of
BIOCERA-VET® product range, which is now available in the five
continents.
Thanks to this agreement with Vetpharma, BIOCERA-VET will be
distributed in Scandinavia (i.e., Norway, Sweden, Denmark and
Finland), in Eastern Europe (i.e., Poland, Bulgaria, Romania, Czech
Republic, Croatia and Hungary), in LATAM countries (i.e., Brazil,
Mexico, Colombia, Argentina, Chile and Peru), in South Africa,
Australia and in selected Asian countries (i.e., Japan, Indonesia,
Philippines, Vietnam, Thailand & South Korea).
Altogether this agreement covers 24 countries representing over
150 million of dogs1,2,3,4 and where the awareness of animal
healthcare needs is currently increasing, particularly in major
countries like the Scandinavians, Australia, Japan, South Africa
and Brazil where a CAGR of 13.1% is forecasted from 2022 to 2027
for the animal healthcare market5.
Under the terms of the agreement, Vetpharma will leverage its
46-year experience in the marketing of veterinary products to
promote and distribute BIOCERA-VET® in these new promising
regions.
Jose Maria, Managing Director at Vetpharma
comments: “We are very pleased to announce this exclusive
distribution agreement with Theravet. The BIOCERA-VET® range of
products allows us to expand our offer with new, innovative, and
highly effective solutions for veterinarians; as well as
contributing to improve the quality of life of our pets.”
About TheraVet SA
TheraVet is a veterinary biotechnology company specialising in
osteoarticular treatments for companion animals. The Company
develops targeted, safe and effective treatments to improve the
quality of life of pets suffering from joint and bone diseases. For
pet owners, the health of their pets is a major concern and
TheraVet’s mission is to address the need for innovative and
curative treatments. TheraVet works closely with international
opinion leaders in order to provide a more effective response to
ever-growing needs in the field of veterinary medicine. TheraVet is
listed on Euronext Growth® Paris and Brussels, has its head office
in Belgium (Gosselies) with a US subsidiary in Texas.
For more information, visit the TheraVet website or follow us on
LinkedIn / Facebook / Twitter
About Vetpharma
Vetpharma is the veterinary division of Chemo, part of the Insud
Pharma group, providing Animal Health solutions. Located in
Barcelona, where the group was founded in 1977, Vetpharma counts on
a highly qualified team with extensive experience in development,
registration and marketing of veterinary medicinal products, API’s
and nutraceuticals.
For more information, visit Vetpharma website.
About BIOCERA-VET
In close collaboration with an international scientific board,
THERAVET® has developed a new line of calcium-phosphate and
biological bone substitutes, BIOCERA-VET®. BIOCERA-VET® is a full
range of innovative, easy-to-use, efficient & cost-effective
bone substitutes indicated in bone surgeries where a bone graft is
required and as a palliative alternative in the management of
canine osteosarcoma. Based on extremely promising clinical results,
this line offers the possibility of a better, more convenient and
more efficient orthopedic surgery.
BIOCERA-VET® is declined in different lines:
- BIOCERA-VET® BONE SURGERY RTU, ready-to-use highly injectable
self-hardening calcium-phosphate cement
- BIOCERA-VET® SMARTGRAFT, a naturally osteoconductive bone
graft
- BIOCERA-VET® GRANULES, an affordable biocompatible
calcium-phosphate bone substitute
- BIOCERA-VET® OSTEOSARCOMA RTU, a ready-to-use highly injectable
calcium-phosphate bone substitute for cementoplasty
For more information, visit BIOCERA-VET website.
1 Global state of Pet Care, Health for animal report 2
https://petkeen.com/ 3 Annual Report Fediaf, 2020 4 Statistica,
2023 5 Market Data Forecast, Latin America Companion Animal
Healthcare market, 2022
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230220005214/en/
TheraVet Chief Operating Officer Sabrina Ena
investors@thera.vet Tel: +32 (0) 71 96 00 43
Chief Corporate Officer Julie Winand
investors@thera.vet
NewCap Investor Relations and Financial Communications
Théo Martin/Nicolas Fossiez theravet@newcap.eu Tel: +33 (0)1 44 71
94 94
Press Relations Arthur Rouillé theravet@newcap.eu Tel: +33 (0)1
44 71 00 15
NewCap Belgique Press Relations Laure-Eve Monfort
lemonfort@newcap.fr Tel: + 32 (0) 489 57 76 52
TheraVet (EU:ALVET)
Historical Stock Chart
From Feb 2024 to Mar 2024
TheraVet (EU:ALVET)
Historical Stock Chart
From Mar 2023 to Mar 2024